Novel therapeutic strategies for AML in 2012

References

• Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al.. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–94.
   Web of Science ®Google Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63.
   Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al.. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331(14):896–903.
   Web of Science ®Google Scholar
• Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al.. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–18.
   Web of Science ®Google Scholar
• Rolling C, Bornahuser M, Thiede C, et al.. Allogeneic stem cell transplantation cnfers favorable outcome in patients with NPM1 positive acute myeloid leukemia: results from a donor vs. no donor analysis of 309 patients treated in the SAL AML-2003 trial. Blood. 2011;abstract 493.
   Google Scholar
• Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al.. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463–8.
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al.. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904–11.
   PubMed Web of Science ®Google Scholar
• Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, et al.. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101–7.
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, et al.. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658–65.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al.. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–59.
   Google Scholar
• Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al.. Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77.
   PubMed Web of Science ®Google Scholar
• Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al.. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trials comparing the addition of Gemtuzumab Ozogamicin to standard induction therapy versus post-consolidation Gemtuzumab Ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood. 2009;114:326–7.
   Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al.. Fractionated doses of gentuzumab ozogamicin (GO) combined with standard chemotherapy (CT) improve event-free and overall survival in newly diagnosed de novo AML patients aged 50–70 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA). Blood. 2011;abstract 6.
   Google Scholar
• Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al.. Attempts to optimise induction and consolidation chemotherapy in patients with acute myeloid leukaemia: results of the MRC AML15 trial. Blood. 2009;114:abstr 484.
   Google Scholar
• Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al.. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.
   PubMed Web of Science ®Google Scholar
• Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE, et al.. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010;24(7):1276–82.
   PubMed Web of Science ®Google Scholar
• Woolfrey A, Lee SJ, Gooley TA, Malkki M, Martin PJ, Pagel JM, et al.. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transplant. 2010;16(10) :1382–7.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, et al.. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relasped or primary refractory acute myeloid leukemia. J Clin Oncol. 2009;27(28):4741–6.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, et al.. First-In-Man Study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29(8):979–85.
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al.. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Blood. 2010;116: abstr 780.
   Google Scholar
• Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, et al.. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567–71.
   Web of Science ®Google Scholar
• Cortes JE, Ghirdaladze D, Foran JM, DeVetten MP, Zodelava M, Levis MJ, et al.. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a First-in-Human phase 1 AML study. Blood. 2009;114(22):abstr 636.
   Google Scholar
• Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, et al.. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28(4):521–3.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Garcia-Manero G, O’Brien S, Faderl S, Ravandi F, Westwood R, et al.. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010;28(2):285–91.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Selceres MA, et al.. A phase II multicentre study with elacytarabine as second salvage therapy in patients with AML. Blood. 2009;114(22): abstr 1042.
   Google Scholar
• Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics T, Damon LE, et al.. Phase 2B randomized study of CPX-351 vs. cytarabine (CYT)+daunorubicin (DNR) (7+3 regimen) in newly diagnosed AML patients aged 60–75. Blood. 2010;116(21): abstr 655.
   Google Scholar